DOCSLIB.ORG

Investing in Our Securities Involves Significant Risks. See “Risk Factors” Beginning on Page S-5 of This Prospectus Supplement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Investing in Our Securities Involves Significant Risks. See “Risk Factors” Beginning on Page S-5 of This Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-151593 PROSPECTUS SUPPLEMENT (To Prospectus dated June 19, 2008) 3,848,289 Shares of Common Stock Warrants to Purchase 1,731,724 Shares of Common Stock We are offering up to 3,848,289 shares of our common stock and warrants to purchase up to 1,731,724 shares of our common stock in this offering (and the shares of common stock issuable from time to time upon exercise of these warrants). The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.45 of a share of common stock at an exercise price of $7.37 per share of common stock. Each unit will be sold at a negotiated price of $6.75625 per unit. Units will not be issued or certificated. The shares of common stock and warrants are immediately separable and will be issued separately. Our common stock is listed on The NASDAQ Global Market under the symbol “JAZZ.” On July 15, 2008, the closing consolidated bid price of our common stock on The NASDAQ Global Market was $6.70 per share. We are offering these shares of common stock and warrants to purchase common stock on a best efforts basis primarily to institutional investors and to certain of our existing investors. We have retained Lazard Capital Markets LLC to act as lead placement agent and Leerink Swann LLC to act as co- placement agent in connection with this offering. Investing in our securities involves significant risks. See “Risk Factors” beginning on page S-5 of this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. Maximum Per Unit Offering Amount Public offering price $6.75625 $26,000,002.56 Placement agents’ fee $0.32482 $ 1,250,000.00 Proceeds, before expenses, to us $6.43143 $24,750,002.56 We estimate the total expenses of this offering, excluding the placement agents’ fees, will be approximately $250,000. Because there is no minimum offering amount required as a condition to closing in this offering, the actual offering amount and net proceeds to us, if any, in this offering may be substantially less than the total maximum offering amounts set forth above. We are not required to sell any specific number or dollar amount of the units offered in this offering, but the placement agents will use their commercially reasonable best efforts to arrange for the sale of all of the units offered. Pursuant to an escrow agreement among us, the placement agents and an escrow agent, some or all of the funds received in payment for the units sold in this offering will be wired to a non-interest bearing escrow account and held until we and the placement agents notify the escrow agent that this offering has closed, indicating the date on which the shares and warrants are to be delivered to the purchasers and the proceeds are to be delivered to us. LAZARD CAPITAL MARKETS LEERINK SWANN Prospectus Supplement dated July 15, 2008. Table of Contents TABLE OF CONTENTS Prospectus Supplement Page About this Prospectus Supplement S-i Prospectus Supplement Summary S-1 Risk Factors S-5 Use of Proceeds S-32 Dilution S-33 Description of Securities We Are Offering S-34 Plan of Distribution S-36 Legal Matters S-37 Prospectus Page About This Prospectus 1 Jazz Pharmaceuticals, Inc. 2 Risk Factors 3 Disclosure Regarding Forward-Looking Statements 3 The Securities We May Offer 4 Ratio of Earnings to Fixed Charges 6 Use of Proceeds 6 Description of Capital Stock 7 Description of Debt Securities 10 Description of Warrants 17 Description of Units 19 Legal Ownership of Securities 20 Plan of Distribution 23 Legal Matters 24 Experts 24 Where You Can Find Additional Information 24 ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is the prospectus supplement, which describes the specific terms of the securities we are offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part, the accompanying prospectus, including the documents incorporated by reference, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date — for example, a document incorporated by reference in the accompanying prospectus — the statement in the document having the later date modifies or supersedes the earlier statement. You should rely only on the information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus and any related free writing prospectus that we authorized to be distributed to you. We have not, and the placement agents have not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and warrants to purchase common stock and the distribution of this prospectus outside the United States. You S-i Table of Contents should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we authorized to be delivered to you is accurate only as of the respective dates of those documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus and any related free writing prospectus that we authorized to be delivered to you when making your investment decision. You should also read and consider the information in the documents we have referred you to in the section of the accompanying prospectus entitled “Where You Can Find Additional Information.” S-ii Table of Contents PROSPECTUS SUPPLEMENT SUMMARY This summary highlights certain information about us, this offering and information appearing elsewhere in this prospectus supplement, in the accompanying prospectus and in the documents we incorporate by reference. This summary is not complete and does not contain all of the information that you should consider before investing in our securities. To fully understand this offering and its consequences to you, you should read this entire prospectus supplement and the accompanying prospectus carefully, including the factors described under the heading “Risk Factors” in this prospectus supplement beginning on page S-5, and the financial statements and other information incorporated by reference in this prospectus supplement and the accompanying prospectus when making an investment decision. About Jazz Pharmaceuticals, Inc. Our Business We are a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Our goal is to build a broad portfolio of products through a combination of internal development and acquisition and in-licensing activities, and to utilize our specialty sales force to promote our products in our target markets. We apply novel formulations and drug delivery technologies to known drug compounds, and to compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by, among other things, improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. By working with these drug compounds, we believe that we can substantially mitigate the risks and reduce the costs and time associated with product development and commercialization of new therapies with significant market opportunities. Through the application of novel formulations and drug delivery technologies, we also explore potential new indications for known drug compounds. Since our inception in 2003, we have built a commercial operation and assembled a portfolio of products and product candidates that currently includes three marketed products and four product candidates in various stages of clinical development. We also have additional product candidates in earlier stages of development. Our marketed products are: • Xyrem® (sodium oxybate) oral solution. Xyrem is the only product approved by the U.S. Food and Drug Administration, or FDA, for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy. Narcolepsy is a chronic neurologic disorder caused by the brain’s inability to regulate sleep-wake cycles. According to the National Institutes of Health, 150,000 or more individuals in the United States are affected by narcolepsy. We promote Xyrem in the United States to neurologists, psychiatrists, pulmonologists and sleep specialists through our approximately 200 person specialty sales force. We have significantly increased U.S. sales of Xyrem since acquiring rights to Xyrem in June 2005. We have licensed the rights to commercialize Xyrem in 54 countries outside of the United States to UCB Pharma Limited, or UCB, and in Canada to Valeant Canada Limited, or Valeant.
Load more

Recommended publications
  • Toward the Uncertificated Security: a Congressional Lead for States to Follow Egon Guttman
    Washington and Lee Law Review Volume 37 | Issue 3 Article 2 Summer 6-1-1980 Toward the Uncertificated Security: A Congressional Lead for States to Follow Egon Guttman Follow this and additional works at: https://scholarlycommons.law.wlu.edu/wlulr Part of the Securities Law Commons Recommended Citation Egon Guttman, Toward the Uncertificated Security: A Congressional Lead for States to Follow, 37 Wash. & Lee L. Rev. 717 (1980), https://scholarlycommons.law.wlu.edu/wlulr/vol37/iss3/2 This Article is brought to you for free and open access by the Washington and Lee Law Review at Washington & Lee University School of Law Scholarly Commons. It has been accepted for inclusion in Washington and Lee Law Review by an authorized editor of Washington & Lee University School of Law Scholarly Commons. For more information, please contact [email protected]. Washington and Lee Law Review Member of the National Conference of Law Reviews Volume XXXVII Summer 1980 Number 3 TOWARD THE UNCERTIFICATED SECURITY: A CONGRESSIONAL LEAD FOR STATES TO FOLLOW* EGON GUTTMAN** The development of the concept of the uncertificated security and of the policy leading to the immobolization of the certificated security was accelerated by the "paperwork crunch" of the late 1960's.1 An explosion in the volume of trading had occurred. A system designed to handle an average three million share trading day was incapable of dealing with the thirteen million share trading day common in the late 1960's.2 The resul- tant breakdown in the securities processing mechanism caused chaos as the number of errors in recording transactions multiplied.3 The securities * 1980 Egon Guttman ** Professor of Law, Washington College of Law, the American University; Visiting Professor of Law, Howard University Law School; Adjunct Professor, The Johns Hopkins University.
    [Show full text]
  • MITEK SYSTEMS, INC. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents As filed with the Securities and Exchange Commission on January 3, 2017 Registration No. 333-215182 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pre-Effective Amendment No. 1 to Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MITEK SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 87-0418827 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 600 B Street, Suite 100 San Diego, CA 92101 (619) 269-6800 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) James B. DeBello President and Chief Executive Officer Mitek Systems, Inc. 600 B Street, Suite 100 San Diego, CA 92101 (619) 269-6800 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Carl Sanchez, Esq. Paul Hastings LLP 4747 Executive Drive, 12th Floor San Diego, CA 92121 (858) 458-3000 From time to time after the effective date of this Registration Statement. (Approximate date of commencement of proposed sale to the public) If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐ If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒ If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
    [Show full text]
  • 200000000 Bofa Merrill Lynch JP Morgan BMO Capital Markets
    Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-221935 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933. The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to Completion Preliminary Prospectus Supplement dated August 6, 2018 PRELIMINARY PROSPECTUS SUPPLEMENT (to prospectus dated December 7, 2017) $200,000,000 Class A common stock We are offering up to shares of our Class A common stock, par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus. Holders of our Class A common stock have no voting rights, except as required by Delaware law. Only the holders of our common stock and Class B common stock vote for the election of directors and on most other matters. Our Class A common stock is traded on the NASDAQ Global Select Market under the symbol “CENTA.” On August 3, 2018, the last reported sale price of our Class A common stock on the NASDAQ Global Select Market was $40.28 per share. Investing in our Class A common stock involves risks. See “Risk Factors” beginning on page S-11 of this prospectus supplement, on page 2 of the accompanying prospectus and in the documents incorporated or deemed incorporated by reference into this prospectus supplement before investing in our Class A common stock.
    [Show full text]
  • Accrued Interest – the Interest Due on a Bond Since the Last Interest Payment Was Made
    A Accrued interest – The interest due on a bond since the last interest payment was made. The buyer of the bond pays the market price plus accrued interest. Acquisition – The acquiring of control of one corporation by another. In "unfriendly" takeover attempts, the potential buying company may offer a price well above current market values, new securities and other inducements to stockholders. The management of the subject company might ask for a better price or try to join up with a third company. American Depositary Receipt (ADR) – a security issued by a U.S. bank in place of the foreign shares held in trust by that bank, thereby facilitating the trading of foreign shares in U.S. markets. American Stock Exchange (AMEX) – The second largest stock exchange in the United States, located in the financial district of New York City. Amortization – Accounting for expenses or charges as applicable rather than as paid. Includes such practices as depreciation, depletion, write-off of intangibles, prepaid expenses and deferred charges. Annual report – The formal financial statement issued yearly by a corporation. The annual report shows assets, liabilities, revenues, expenses and earnings - how the company stood at the close of the business year, how it fared profit-wise during the year, as well as other information of interest to shareowners. Arbitrage – A technique employed to take advantage of differences in price. If, for example, ABC stock can be bought in New York for $10 a share and sold in London at $10.50, an arbitrageur may simultaneously purchase ABC stock here and sell the same amount in London, making a profit of $.50 a share, less expenses.
    [Show full text]
  • Important Account Information Please Read This Booklet Carefully and Retain for Your Records Contents 4 General Information for All Accounts 4 U.S
    Important Account Information Please read this booklet carefully and retain for your records Contents 4 General Information for all Accounts 4 U.S. Customer Privacy Notice 7 Brazilian Data Protection Notification 7 Summary of Account Types Offered at Morgan Stanley 8 Conflicts of Interest and Other Information 13 Account Linking Service 13 Electronic Delivery (eDelivery) 14 European Securities Subject to the Shareholder Rights Directive II 15 Disclosure of Your Name to Issuers of Securities 15 Tax & Legal Disclosure 15 The USA PATRIOT Act 15 Understanding Your Brokerage and Investment Advisory Relationships 18 Account Protection 19 FDIC Insurance 19 Business Continuity Management Program and Technology Disaster Recovery Program Overview 21 Trusted Contact Authorization 21 Investing and Trading 23 Summary of Procedures for Certain Syndicate Offerings 24 Market Transition Away from LIBOR 26 Important Information Regarding the Sales and Offers of Sales of Investment Products to U.S. Military Personnel and Their Dependents 26 Important Information for Clients Effecting Short Sales and/or Holding Short Stock Positions 26 Summary of the Bank Deposit Program 30 How Morgan Stanley and Your Financial Advisor Are Compensated 33 Your Account and Service Fees 41 Quarterly Automatic Liquidation of Securities for Outstanding Account and Service Fee Debits 41 Important Information About Certain Investment Product Fees and Other Costs 41 GlobalCurrencySM Accounts 42 Morgan Stanley Reserved Living & Giving 42 Incoming Foreign Currency Wires 43 Morgan
    [Show full text]
  • MYOVANT SCIENCES LTD. (Exact Name of Registrant As Specified in Its Charter) Bermuda 98-1343578 (State Or Other Jurisdiction of Incorporation Or Organization) (I.R.S
    TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 19, 2020 Registration No. 333-231764 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOVANT SCIENCES LTD. (Exact name of registrant as specified in its charter) Bermuda 98-1343578 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Suite 1, 3rd Floor 11-12 St. James’s Square London SW1Y 4LB United Kingdom 44 (207) 400-3351 (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices) Corporation Service Company 251 Little Falls Drive Wilmington, DE 19808-1674 (800) 927-9800 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Kenneth Guernsey Matthew Lang Frank Karbe Brett White General Counsel and Corporate Principal Financial and Accounting Officer Cooley LLP Secretary Myovant Sciences Ltd. 3175 Hanover Street Myovant Sciences Ltd. c/o Myovant Sciences, Inc. Palo Alto, CA 94304 c/o Myovant Sciences, Inc. 2000 Sierra Point Parkway, 9th Floor (650) 843-5000 2000 Sierra Point Parkway, 9th Brisbane, CA 94005 Floor (650) 238-0250 Brisbane, CA 94005 (650) 238-0250 Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement. If the only securities being registered on this form are being offered pursuant
    [Show full text]
  • CELL THERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents As filed with the Securities and Exchange Commission on February 16, 2011 Registration No. 333-161442 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CELL THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Washington 2834 91-1533912 (State of other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) 501 Elliott Avenue West, Suite 400 Seattle, Washington 98119 (206) 282-7100 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) James A. Bianco, M.D. Chief Executive Officer Cell Therapeutics, Inc. 501 Elliott Avenue West, Suite 400 Seattle, Washington 98119 (206) 282-7100 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copy to: C. Brophy Christensen, Jr., Esq. Todd A. Hamblet, Esq. O’Melveny & Myers LLP Two Embarcadero Center, 28th Floor San Francisco, California 94111-3823 (415) 984-8700 Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement. If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨ Table of Contents If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.
    [Show full text]
  • Up to $75000000 of Shares Common Stock Jefferies
    Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-234414 PROSPECTUS SUPPLEMENT (To Prospectus dated November 22, 2019) Up To $75,000,000 of Shares Common Stock We have entered into an Open Market Sale Agreement SM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock, $0.00001 par value per share, from time to time having an aggregate offering price of up to $75.0 million through Jefferies, acting as our sales agent. Our common stock is traded on The Nasdaq Global Market under the symbol "PTGX." On November 26, 2019, the last reported sale price of our common stock was $7.80 per share. Sales of our shares, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Jefferies is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Jefferies and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
    [Show full text]
  • Cantor Oppenheimer &
    TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-238996 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 15, 2020) Up to $100,000,000 American Depositary Shares representing Ordinary Shares In accordance with the terms of the Controlled Equity OfferingSM Sales Agreement, or sales agreement, dated as of June 5, 2020, with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc., or, collectively, the Sales Agents, we may offer and sell American Depositary Shares, or ADSs, representing our ordinary shares, having an aggregate offering price of up to an additional $100,000,000 from time to time through the Sales Agents pursuant to this prospectus supplement. Our ADSs are listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol “BCYC.” On May 21, 2021, the last reported sale price of our ADSs was $30.71 per ADS. Sales of our ADSs, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through Nasdaq or any other existing trading market for our ADSs. The Sales Agents are not required to sell any specific number or dollar amount of securities. Neither of the Sales Agents is required to sell any specific number or dollar amount of securities, but each has agreed to use its commercially reasonable efforts to sell on our behalf all of the ADSs requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms among the Sales Agents and us.
    [Show full text]
  • Jefferies Stifel Nicolaus Weisel
    Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-185721 PROSPECTUS SUPPLEMENT (To Prospectus dated January 4, 2013) 4,000,000 Shares NewLink Genetics Corporation Common Stock We are offering up to 4,000,000 shares of our common stock. Our common stock is listed on the NASDAQ Global Market under the symbol “NLNK”. On January 29, 2013, the last reported sale price of our common stock on the NASDAQ Global Market was $11.40 per share. Investing in our common stock involves a high degree of risk. Please read “Risk Factors” beginning on page S-4 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. PER SHARE TOTAL Public Offering Price $ 11.400 $ 45,600,000 Underwriting Discounts and Commissions $ 0.684 $ 2,736,000 Proceeds, Before Expenses, to Us $ 10.716 $ 42,864,000 Stine Seed Farm, Inc., an existing stockholder, has agreed to purchase $10 million of shares of common stock in this offering at the price offered to the public. Delivery of the shares of common stock is expected to be made on or about February 4, 2013. We have granted the underwriters an option for a period of 30 days to purchase an additional 600,000 shares of our common stock. If the underwriters exercise their option in full, the total underwriting discounts and commissions payable by us will be $3,146,400, and the total proceeds to us, before expenses, will be $49,293,600.
    [Show full text]
  • 1.Origen De Bolsa De Valores Y Financiamiento
    1.ORIGEN DE BOLSA DE VALORES Y FINANCIAMIENTO 1.1. OBJETIVO GENERAL Identificar la importancia del origen de la Bolsa de Valores de una forma completa y actualizada. 1.2. OBJETIVOS ESPECÍFICOS - Identificar cómo se formó la Bolsa de Valores. - Distinguir entre los dos mercados principales de E.E.U.U. - Analizar la importancia del intercambio de acciones en New York Stock Exchange (NYSE) - Analizar la importancia del papel que juega la Bolsa en diversos aspectos como la economía, la empresa y el individuo. 1.3. BOLSA DE VALORES Y FINANCIAMIENTO La mercancía básica del sistema financiero es el dinero. El dinero sirve como intercambio donde todas las formas de dinero que se han utilizado han sido desde cacao, plata, oro, dientes de ballena, piedras, pero éstas han llegado a la obsolescencia. Entre las tres grandes funciones el dinero es reconocido como un medio de cambio, que a la vez representa una medida de valor y como una forma de mantener riqueza. El dinero se puede representar en tres formas: dinero en efectivo, dinero en cuentas corrientes y dinero electrónico. La función de concentrar, reproducir, reciclar y multiplicar el dinero está a cargo del sistema financiero. En el sistema financiero es donde se compra, se fija el precio y donde se vende el dinero. Al ser el dinero un factor de intercambio, la eficiencia de éste es para generar bienestar lo cual depende de un sistema financiero que opere con transparencia, fluidez y orden. 1.4. ORIGEN DE LA BOLSA DE VALORES Los mercados de valores son oxígeno para la economía ya que absorben, expanden y dan el fluido que todas las economías necesitan que es el dinero.
    [Show full text]
  • Investing in Our Securities Involves Significant Risks
    Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-165663 PROSPECTUS SUPPLEMENT (To Prospectus dated April 2, 2010) 30,293,000 Units Each Unit Consisting of One Share of Common Stock One Warrant to Purchase 0.5 of a Share of Common Stock We are offering 30,293,000 units, each of which consists of one share of our common stock and one warrant to purchase 0.5 of a share of common stock. The units are being offered at a per unit price of $1.4525. Units will not be issued or certificated. The shares of common stock and warrants will be issued separately and will be immediately separable. Each warrant has an exercise price of $1.50 per share, and is exercisable for a period of five years from the date of issuance. Our common stock is listed on the NASDAQ Capital Market under the symbol “DVAX.” The last reported sale price of our common stock on April 12, 2010 was $1.39 per share. The warrants will not be listed on any exchange and we do not expect that a public market for the warrants will develop. Investing in our securities involves significant risks. See “Risk Factors ” beginning on page S-5 of this prospectus supplement and the risk factors contained in our filings with the Securities and Exchange Commission which have been incorporated herein. Per Unit Total Public offering price $ 1.4525 $44,000,583 Underwriting discount $0.08715 $ 2,640,035 Proceeds, before expenses, to us $1.36535 $41,360,548 Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
    [Show full text]